According to media reports, Biocon Biologics said on Tuesday the US Food and Drug Administration (US FDA) has approved the Indian group’s first-to-file application for Yesafili, an interchangeable biosimilar of aflibercept. Yesafili treats various eye disorders, including neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema secondary to retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. The medication is similar to the reference product Eylea (aflibercept). Studies demonstrate that Yesafili matches Eylea in quality, safety, and efficacy.
As per the sources, “Yesafili is approved for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy,” said Tambe. Biocon Biologics said the nod for Yesafili marks the company’s entry into the ophthalmology market in the United States, following successful approvals in Europe (September 2023) and the United Kingdom (November 2023), where it became the first biosimilar aflibercept approved. The company has also secured a launch date in Canada for July 1, 2025, as part of a settlement agreement. In the US, 19.8 million people live with AMD. In 2023, sales of aflibercept, a common treatment for AMD, reached approximately $5.89 billion.
#dailyaawaz #newswebsite #news #newsupdate #hindinews #breakingnews #headlines #headline #newsblog #hindisamachar #latestnewsinhindi
Hindi news, हिंदी न्यूज़ , Hindi Samachar, हिंदी समाचार, Latest News in Hindi, Breaking News in Hindi, ताजा ख़बरें
